In­tra-Cel­lu­lar's check­ered de­vel­op­men­tal path ends in schiz­o­phre­nia ap­proval, shares sky­rock­et

It may be al­most the end of the year, but the FDA’s sta­mi­na for ap­provals has per­se­vered.

On Mon­day, In­tra-Cel­lu­lar Ther­a­pies se­cured the reg­u­la­tor’s bless­ing for its an­tipsy­chot­ic drug, Caply­ta, de­spite two late-stage schiz­o­phre­nia stud­ies that left much to be de­sired. But as is cus­tom with most an­tipsy­chotics, tri­als that fall short typ­i­cal­ly do not nec­es­sar­i­ly de­ter a drug’s path to ap­proval.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER